To appraise the clinical and cost effectiveness of cannabidiol within its marketing authorisation for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome.
 
Status In progress
Process STA 2018
ID number 1308

Provisional Schedule

Committee meeting: 1 30 July 2019
Expected publication 18 December 2019

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews

Consultees

Companies sponsors GW Pharma
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Dravet Syndrome UK
  Epilepsy Action
  Epilepsy Society
Professional groups Association of British Neurologists
  Primary Care and Community Neurology Society
  Royal College of Physicians

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (clobazam, topiramate) (not participating)
  Atnahs Pharma UK (clobazam) (not participating)
  Aurobindo Pharma - Milpharm (topiramate) (not participating)
  Biocodex (stiripentol) (not participating)
  Desitin Pharma (sodium valproate) (not participating)
  Janssen (topiramate) (not participating)
  Martindale Pharma (clobazam) (not participating)
  Mylan (topiramate) (not participating)
  Rosemont Pharmaceuticals (clobazam) (not participating)
  Sandoz (topiramate) (not participating)
  Sanofi (clobazam, sodium valproate) (not participating)
  Thame Laboratories (clobazam) (not participating)
  Wockhardt UK (sodium valproate) (not participating)
  Zentiva (sodium valproate) (not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Epilepsy Group

Timeline

Key events during the development of the guidance:

Date Update
14 March 2019 The date of the first Committee meeting has been amended to 30 July 2019.
31 October 2018 In progress, The invitation to participate was sent to stakeholders.
31 October 2018 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance